3 Pharma Groups: Limit Scope of Off-Year Re-Pricing to Drugs with “Significantly Large Discrepancy Rates”

Three major pharma industry groups of Japan, the US, and Europe on November 25 renewed their call for a careful approach to “off-year” drug re-pricing slated for next April, while pushing for a general off-cycle revision rule that would limit...read more